Objective—To determine the odds of moderate or
severe gastric ulceration in racehorses treated with
various antiulcer medications.
Design—Unmatched case-control study.
Animals—798 horses in active race training (252
Thoroughbreds and 546 Standardbreds). Only horses
that had been receiving a single antiulcer medication
or no antiulcer medication for at least 2 weeks prior to
examination were included.
Procedure—Gastroscopy was performed on each
horse by a single individual who was not aware of the
horses' antiulcer treatments, and severity of gastric
ulceration was scored. Signalment and medication
history were recorded. Logistic regression was used
to determine whether identification of moderate or
severe ulceration was associated with treatment,
age, breed, or sex. Treatments were grouped as no
treatment, buffer, sucralfate, histamine type 2 receptor
antagonist, compounded omeprazole, proprietary
omeprazole at a low dosage, and proprietary omeprazole
at a high dosage.
Results—Only proprietary omeprazole was associated
with significantly lower odds of moderate or
severe ulceration, compared with no treatment. Risks
of moderate or severe gastric ulceration in horses
receiving a buffer, sucralfate, a histamine type 2
receptor antagonist, or compounded omeprazole
were not significantly different from risks in horses
receiving no antiulcer medication.
Conclusions and Clinical Relevance—Results suggest
that the proprietary formulation of omeprazole
was associated with a significantly lower risk of moderate
or severe gastric ulceration, compared with no
treatment, in racehorses in active race training,
whereas other antiulcer medications were not. (J Am
Vet Med Assoc 2003;223:336–339)